skip to main content
Idioma:
Resultados 1 2 3 next page
Refinado por: Base de dados/Biblioteca: Academic Search Premier remover assunto: Oncology remover Adult remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab
Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab
Material Type:
Artigo 		Adicionar ao Meu Espaço

Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab

Custodio, A ; Carmona-Bayonas, A ; Jiménez-Fonseca, P ; Sánchez, M L ; Viudez, A ; Hernández, R ; Cano, J M ; Echavarria, I ; Pericay, C ; Mangas, M ; Visa, L ; Buxo, E ; García, T ; Rodríguez Palomo, A ; Álvarez Manceñido, F ; Lacalle, A ; Macias, I ; Azkarate, A ; Ramchandani, A ; Fernández Montes, A ; López, C ; Longo, F ; Sánchez Bayona, R ; Limón, M L ; Díaz-Serrano, A ; Hurtado, A ; Madero, R ; Gómez, C ; Gallego, J

British journal of cancer, 2017-06, Vol.116 (12), p.1526-1535 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por
2
Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation
Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation
Material Type:
Artigo 		Adicionar ao Meu Espaço

Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation

Fernandes, Gustavo S ; Girardi, Daniel M ; Bernardes, João Paulo G ; Fonseca, Felipe P ; Fregnani, Eduardo R

BMC cancer, 2018-09, Vol.18 (1), p.887-887, Article 887 [Periódico revisado por pares]

England: BioMed Central Ltd

Texto completo disponível

Citações Citado por
3
Genetic aberrations and survival in plasma cell leukemia
Genetic aberrations and survival in plasma cell leukemia
Material Type:
Artigo 		Adicionar ao Meu Espaço

Genetic aberrations and survival in plasma cell leukemia

TIEDEMANN, R. E ; GONZALEZ-PAZ, N ; GREIPP, P. R ; DISPENZIERI, A ; LACY, M. Q ; RAJKUMAR, S. V ; BERGSAGEL, P. L ; STEWART, A. K ; FONSECA, R ; KYLE, R. A ; SANTANA-DAVILA, R ; PRICE-TROSKA, T ; VAN WIER, S. A ; CHNG, W. J ; KETTERLING, R. P ; GERTZ, M. A ; HENDERSON, K

Leukemia, 2008-05, Vol.22 (5), p.1044-1052 [Periódico revisado por pares]

London: Nature Publishing

Texto completo disponível

Citações Citado por
4
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project
Material Type:
Artigo 		Adicionar ao Meu Espaço

Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project

Avet-Loiseau, H ; Durie, B G M ; Cavo, M ; Attal, M ; Gutierrez, N ; Haessler, J ; Goldschmidt, H ; Hajek, R ; Lee, J H ; Sezer, O ; Barlogie, B ; Crowley, J ; Fonseca, R ; Testoni, N ; Ross, F ; Rajkumar, S V ; Sonneveld, P ; Lahuerta, J ; Moreau, P ; Morgan, G

Leukemia, 2013-03, Vol.27 (3), p.711-717 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por
5
Thalidomide as initial therapy for early-stage myeloma
Thalidomide as initial therapy for early-stage myeloma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Thalidomide as initial therapy for early-stage myeloma

RAJKUMAR, S. V ; GERTZ, M. A ; GREIPP, P. R ; WITZIG, T. E ; LACY, M. Q ; DISPENZIERI, A ; FONSECA, R ; GEYER, S. M ; ITURRIA, N ; KUMAR, S ; LUST, J. A ; KYLE, R. A

Leukemia, 2003-04, Vol.17 (4), p.775-779 [Periódico revisado por pares]

London: Nature Publishing

Texto completo disponível

Citações Citado por
6
Intranasal perillyl alcohol therapy improves survival of patients with recurrent glioblastoma harboring mutant variant for MTHFR rs1801133 polymorphism
Intranasal perillyl alcohol therapy improves survival of patients with recurrent glioblastoma harboring mutant variant for MTHFR rs1801133 polymorphism
Material Type:
Artigo 		Adicionar ao Meu Espaço

Intranasal perillyl alcohol therapy improves survival of patients with recurrent glioblastoma harboring mutant variant for MTHFR rs1801133 polymorphism

Faria, Giselle M ; Soares, Igor D P ; D'Alincourt Salazar, Marcela ; Amorim, Marcia R ; Pessoa, Bruno L ; da Fonseca, Clovis O ; Quirico-Santos, Thereza

BMC cancer, 2020-04, Vol.20 (1), p.294-294, Article 294 [Periódico revisado por pares]

England: BioMed Central Ltd

Texto completo disponível

Citações Citado por
7
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma

KUMAR, S ; DISPENZIERI, A ; GERTZ, M. A ; LACY, M. Q ; HAYMAN, S. R ; BUADI, F. K ; GASTINEAU, D. A ; LITZOW, M. R ; FONSECA, R ; ROY, V ; RAJKUMAR, S. V

Leukemia, 2007-09, Vol.21 (9), p.2035-2042 [Periódico revisado por pares]

London: Nature Publishing

Texto completo disponível

Citações Citado por
8
Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial
Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial

Ailawadhi, S ; Mikhael, J R ; LaPlant, B R ; Laumann, K M ; Kumar, S ; Roy, V ; Dingli, D ; Bergsagel, P L ; Buadi, F K ; Rajkumar, S V ; Fonseca, R ; Gertz, M A ; Kapoor, P ; Sher, T ; Hayman, S R ; Stewart, A K ; Dispenzieri, A ; Kyle, R A ; Gonsalves, W I ; Reeder, C B ; Lin, Y ; Go, R S ; Leung, N ; Kourelis, T ; Lust, J A ; Russell, S J ; Chanan-Khan, A A ; Lacy, M Q

Leukemia, 2018-03, Vol.32 (3), p.719-728 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por
9
Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome
Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome
Material Type:
Artigo 		Adicionar ao Meu Espaço

Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome

Barrio, S ; Shanafelt, T D ; Ojha, J ; Chaffee, K G ; Secreto, C ; Kortüm, K M ; Pathangey, S ; Van-Dyke, D L ; Slager, S L ; Fonseca, R ; Kay, N E ; Braggio, E

Leukemia, 2017-01, Vol.31 (1), p.170-176 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por
10
Pomalidomide (CC4047) plus low dose dexamethasone (Pom dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
Pomalidomide (CC4047) plus low dose dexamethasone (Pom dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Pomalidomide (CC4047) plus low dose dexamethasone (Pom dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

LACY, M. Q ; HAYMAN, S. R ; ZELDENRUST, S ; FONSECA, R ; BERGSAGEL, P. L ; ROY, V ; MIKHAEL, J. R ; STEWART, A. K ; LAUMANN, K ; ALLRED, J. B ; MANDREKAR, S. J ; RAJKUMAR, S. V ; GERTZ, M. A ; BUADI, F ; SHORT, K. D ; DISPENZIERI, A ; KUMAR, S ; GREIPP, P. R ; LUST, J. A ; RUSSELL, S. J ; DINGLI, D

Leukemia, 2010-11, Vol.24 (11), p.1934-1939 [Periódico revisado por pares]

Avenel, NJ: Nature Publishing Group

Texto completo disponível

Citações Citado por
Resultados 1 2 3 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Data de Publicação 

De até
Refinar
  1. Antes de2001  (5)
  2. 2001Até2006  (9)
  3. 2007Até2010  (3)
  4. 2011Até2017  (7)
  5. Após 2017  (3)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.